Elan Reaffirms Positive Outlook For Third Quarter of 2001 and Full Year 2001

Search Blogs that Mention this News Release

Click this link to view linked Bookmarking Services

Click this link to view linked Blogging Services

Elan Reaffirms Positive Outlook For Third Quarter of 2001 and Full Year 2001

    DUBLIN, Ireland, Sept. 19 /PRNewswire/ -- Elan Corporation, plc
(NYSE: ELN) ("Elan") states that it remains comfortable with consensus
estimates for the third quarter and full year 2001.
    In addition, Elan confirms that all of its major development programs and
new product introductions are on track.
    Elan Corporation, plc is a leading worldwide, fully integrated
pharmaceutical company headquartered in Ireland, with its principal research,
development, manufacturing and marketing facilities located in Ireland, the
United States and the United Kingdom.  Elan is focused on the discovery,
development and marketing of therapeutic products and services in neurology,
pain management, oncology, infectious disease and dermatology and on the
development and commercialization of products using its extensive range of
proprietary drug delivery technologies.  Elan shares trade on the New York,
London and Dublin stock exchanges.

SOURCE Elan Corporation, plc

http://www.elan.ie
Company News On-Call:

http://www.prnewswire.com/comp/231593.html
CONTACT:
Investors - U.S. - Jack Howarth,
+1-212-407-5740, or +1-800-252-3526, or Investors - Europe - Emer
Reynolds, +353-1-709-4000, or 00800-28352600, or Media - Max
Gershenoff, +1-212-407-5740, or +1-800-252-3526, all for Elan
Corporation, plc